Today Adma Biologics (Nasdaq: ADMA) sold off ~10% closing at $3.50. Most of us already in Adma were not phased. Personally, I saw this as a healthy pullback. Since February 1st ADMA has gained 25% … [Read more...] about ADMA Presents Potential Entry For Investors On The Sideline
Introduction Adma Biologics (Nasdaq: ADMA $2.23) is a commercial bio-pharmaceutical company vertically integrated to develop, market, manufacture, and sell specialty plasma-derived products called … [Read more...] about ADMA Tanks After Receiving A CRL For BIVIGAM’s PAS Submission -Should You Buy?
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath